Alto Neuroscience's (ANRO) "Outperform" Rating Reiterated at William Blair

Alto Neuroscience (NYSE:ANRO - Get Free Report)'s stock had its "outperform" rating reiterated by stock analysts at William Blair in a research report issued to clients and investors on Friday,RTT News reports. William Blair also issued estimates for Alto Neuroscience's Q1 2026 earnings at ($0.53) EPS, Q2 2026 earnings at ($0.53) EPS, Q3 2026 earnings at ($0.43) EPS and Q4 2026 earnings at ($0.43) EPS.

Alto Neuroscience Stock Performance

ANRO stock traded up $0.09 on Friday, hitting $2.74. The company's stock had a trading volume of 76,887 shares, compared to its average volume of 308,815. Alto Neuroscience has a 1 year low of $2.58 and a 1 year high of $18.35. The company has a current ratio of 13.10, a quick ratio of 13.09 and a debt-to-equity ratio of 0.05. The stock has a market cap of $73.90 million and a price-to-earnings ratio of -1.08. The firm has a 50 day moving average of $3.63 and a two-hundred day moving average of $6.05.

Alto Neuroscience (NYSE:ANRO - Get Free Report) last announced its earnings results on Thursday, March 20th. The company reported ($0.56) earnings per share for the quarter, topping the consensus estimate of ($0.65) by $0.09. Equities analysts predict that Alto Neuroscience will post -2.54 EPS for the current fiscal year.

Remove Ads

Institutional Trading of Alto Neuroscience

Several hedge funds have recently made changes to their positions in the company. Wells Fargo & Company MN lifted its position in Alto Neuroscience by 40.0% in the fourth quarter. Wells Fargo & Company MN now owns 10,989 shares of the company's stock valued at $46,000 after purchasing an additional 3,139 shares during the period. BNP Paribas Financial Markets lifted its holdings in shares of Alto Neuroscience by 619.2% in the 3rd quarter. BNP Paribas Financial Markets now owns 4,315 shares of the company's stock valued at $49,000 after buying an additional 3,715 shares during the period. Deutsche Bank AG boosted its stake in shares of Alto Neuroscience by 31.3% in the fourth quarter. Deutsche Bank AG now owns 15,210 shares of the company's stock valued at $64,000 after buying an additional 3,629 shares in the last quarter. Skandinaviska Enskilda Banken AB publ acquired a new position in Alto Neuroscience during the fourth quarter worth $74,000. Finally, Jane Street Group LLC raised its position in Alto Neuroscience by 72.0% in the fourth quarter. Jane Street Group LLC now owns 18,600 shares of the company's stock worth $79,000 after acquiring an additional 7,783 shares in the last quarter.

Alto Neuroscience Company Profile

Alto Neuroscience, Inc operates as a clinical-stage biopharmaceutical company in the United States. Its product pipeline comprising ALTO-100, which is in phase 2b clinical trial for the treatment of patients with major depressive disorder (MDD); and which is in phase 2a clinical trial for the treatment of post-traumatic stress disorder.